Late‐onset unexplained epilepsy as a risk factor for cognitive impairment and dementia: Protocol for a multi‐center prospective longitudinal observational study ( ELUCID )
Epilepsia Open · 2026
DOI: 10.1002/epi4.70184 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Epilepsia Open, 2026. Verfasst von Alice D Lam und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Dementia, Cognitive Dysfunction, Epilepsy. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NINDS NIH HHS, NIH HHS, National Institutes of Health.
Themen: Demenz
Abstract (Originalsprache)
Objective Late‐onset unexplained epilepsy (LoUE), defined as epilepsy onset after age 55 without an obvious cause, is an important risk factor for dementia. Studies have shown that 10%–25% of individuals with LoUE develop dementia within 3–4 years following their first seizure. However, the mechanisms underlying progression from LoUE to dementia remain poorly understood. The goals of the ELUCID study are to identify risk factors associated with the development of cognitive decline and dementia in LoUE and to develop tools to identify patients at a high risk for these outcomes and thereby establish a foundation for dementia prevention strategies in this population. Methods and Analysis ELUCID is a multi‐center prospective longitudinal observational study that will enroll 600 participants aged 55 or older with LoUE across seven U.S. medical centers. Participants will undergo a baseline evaluation that includes a detailed clinical history, cognitive testing, brain MRI, overnight scalp EEG, and blood biomarkers. Participants will be followed at 6‐month intervals for up to 5 years, to record cognitive and neurological changes, with the primary outcomes of interest being the development of mild cognitive impairment and/or dementia. This study aims to establish LoUE disease subtypes based on biomarkers, cognitive trajectories, and imaging features and to develop a risk stratification tool for predicting cognitive decline and dementia in patients presenting with LoUE. Ethics and Dissemination ELUCID has obtained IRB approval (no. 2023P001566, August 2023), with the Mass General Brigham IRB serving as the single IRB of record. All de‐identified study data will be made publicly available on completion of the study. Plain Language Summary The ELUCID study is a research project involving several medical centers across the U.S. It will focus on older adults who have recently developed seizures without a clear cause. Participants undergo an initial evaluation that includes questions about their medical history, a brain MRI , an overnight scalp EEG (brain wave study), and a blood draw. They will be followed over time with health questionnaires and yearly tests of memory and thinking. The purpose of the study is to learn what factors increase the risk of dementia in this population and to develop tools to predict which individuals are at the highest risk.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts, USA.
- Harvard Medical School, Boston, Massachusetts, USA.
- Department of Neurology, Johns Hopkins Medicine, Baltimore, Maryland, USA.
- Department of Neurology, Brigham and Women's Hospital, Boston, Massachusetts, USA.
- Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
- Department of Neurology, University of Alabama at Birmingham, Birmingham, Alabama, USA.
ORCID-Profile: Alice D Lam, Emily L Johnson, Rani A Sarkis, Leah J Blank, Tyler E Gaston, Mouhsin M Shafi, Rodrigo Zepeda, Kyle R Pellerin, Nathalie Jette, Douglas N Greve, Lori B Chibnik, Rebecca E Amariglio, Gad A Marshall, M Brandon Westover
Förderung
- NINDS NIH HHS
- NIH HHS
- National Institutes of Health
Zitieren
APA
Lam, A. D., Johnson, E. L., Sarkis, R. A., Blank, L. J., Gaston, T. E., Shafi, M. M., Zepeda, R., Pellerin, K. R., Jette, N., Greve, D. N., Chibnik, L. B., Amariglio, R. E., Marshall, G. A., & Westover, M. B. (2026). Late‐onset unexplained epilepsy as a risk factor for cognitive impairment and dementia: Protocol for a multi‐center prospective longitudinal observational study ( ELUCID ). Epilepsia Open. https://doi.org/10.1002/epi4.70184
Vancouver
Lam AD, Johnson EL, Sarkis RA, Blank LJ, Gaston TE, Shafi MM, et al. Late‐onset unexplained epilepsy as a risk factor for cognitive impairment and dementia: Protocol for a multi‐center prospective longitudinal observational study ( ELUCID ). Epilepsia Open. 2026. doi:10.1002/epi4.70184
BibTeX
@article{Lam2026,
author = {Lam, Alice D and Johnson, Emily L and Sarkis, Rani A and Blank, Leah J and Gaston, Tyler E and Shafi, Mouhsin M and Zepeda, Rodrigo and Pellerin, Kyle R and Jette, Nathalie and Greve, Douglas N and Chibnik, Lori B and Amariglio, Rebecca E and Marshall, Gad A and Westover, M Brandon},
title = {Late‐onset unexplained epilepsy as a risk factor for cognitive impairment and dementia: Protocol for a multi‐center prospective longitudinal observational study ( ELUCID )},
journal = {Epilepsia Open},
year = {2026},
doi = {10.1002/epi4.70184}
}
EUVIMED